CL2017001790A1 - Método para tratar diarrea en animales de compañía - Google Patents

Método para tratar diarrea en animales de compañía

Info

Publication number
CL2017001790A1
CL2017001790A1 CL2017001790A CL2017001790A CL2017001790A1 CL 2017001790 A1 CL2017001790 A1 CL 2017001790A1 CL 2017001790 A CL2017001790 A CL 2017001790A CL 2017001790 A CL2017001790 A CL 2017001790A CL 2017001790 A1 CL2017001790 A1 CL 2017001790A1
Authority
CL
Chile
Prior art keywords
diarrhea
pets
treating diarrhea
proantocianidine
enthermic
Prior art date
Application number
CL2017001790A
Other languages
English (en)
Inventor
Serge Martinod
Original Assignee
Jaguar Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaguar Health Inc filed Critical Jaguar Health Inc
Publication of CL2017001790A1 publication Critical patent/CL2017001790A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Feed For Specific Animals (AREA)

Abstract

<p>SE PROPORCIONAN MÉTODOS Y COMPOSICIONES PARA TRATAR LA DIARREA, PARTICULARMENTE LA DIARREA SECRETORA, LA DIARREA ACUOSA Y LA DIARREA INDUCIDA CON QUIMIOTERAPIA (CID), EN ANIMALES DE COMPAÑÍA NO HUMANOS JÓVENES Y ADULTOS, TALES COMO PERROS Y GATOS, CON UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN POLÍMERO DE PROANTOCIANIDINAS DEL CROTON LECHLERI, YA SEA EN FORMA ENTÉRICA O NO ENTÉRICA.</p>
CL2017001790A 2015-01-09 2017-07-07 Método para tratar diarrea en animales de compañía CL2017001790A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101663P 2015-01-09 2015-01-09
US201562117927P 2015-02-18 2015-02-18

Publications (1)

Publication Number Publication Date
CL2017001790A1 true CL2017001790A1 (es) 2018-04-06

Family

ID=56356484

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001790A CL2017001790A1 (es) 2015-01-09 2017-07-07 Método para tratar diarrea en animales de compañía

Country Status (13)

Country Link
US (1) US20180264061A1 (es)
EP (1) EP3242557A4 (es)
JP (1) JP2018509382A (es)
KR (1) KR20170103834A (es)
CN (1) CN107106536A (es)
AU (1) AU2016205145A1 (es)
BR (1) BR112017014750A2 (es)
CA (1) CA2972996A1 (es)
CL (1) CL2017001790A1 (es)
CO (1) CO2017007823A2 (es)
MX (1) MX2017009011A (es)
RU (1) RU2017127686A (es)
WO (1) WO2016112312A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JP7237014B2 (ja) * 2017-12-27 2023-03-10 サントリーホールディングス株式会社 腸管バリア機能改善用組成物
CA3182864A1 (en) * 2020-06-19 2021-12-23 Lisa A. CONTE Methods and compositions for treating chemotherapy-induced diarrhea
KR102618266B1 (ko) 2023-09-08 2023-12-27 주식회사 모이스텐 반려동물 복용 편의를 고려한 생분해성 필름 및 이의 제조방법
KR102832162B1 (ko) * 2023-12-28 2025-07-09 주식회사 페토바이오 반려동물 의료기록데이터에 기반한 가상 임상시험 시스템 및 운영방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060183A3 (en) * 1996-10-16 2009-06-03 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
EP1921076A1 (en) * 2002-10-11 2008-05-14 Proteotech Inc. systhesis of procyanidin B2
ES2616012T3 (es) * 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
EP2431380A3 (en) * 2006-09-11 2013-07-03 Tranzyme Pharma, Inc. Macrocyclic antagonist of the motilin receptor for treatment of gastrointestinal dysmotility disorders
US8709515B1 (en) * 2009-02-19 2014-04-29 Carmen C. H. Colitz Nutritional supplement method
AU2010303577B2 (en) * 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
CN102138930A (zh) * 2011-01-04 2011-08-03 海南美兰史克制药有限公司 复方雷贝拉唑钠药物组合物固体制剂
BR112014015314A2 (pt) * 2011-12-22 2017-06-13 Glenmark Pharmaceuticals Ltd composição farmacêutica não entérica compreendendo crofelemer
US20170095442A1 (en) * 2014-05-29 2017-04-06 Jaguar Animal Health, Inc. Methods of Treating Salmonella-Induced Diarrhea in Non-Human Animals
US20170100429A1 (en) * 2014-05-29 2017-04-13 Jaguar Animal Health, Inc. Methods of Treating Diarrhea in Neonatal and Young Non-Human Animals
WO2015184109A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in adult non-human animals

Also Published As

Publication number Publication date
RU2017127686A (ru) 2019-02-11
CN107106536A (zh) 2017-08-29
KR20170103834A (ko) 2017-09-13
AU2016205145A1 (en) 2017-07-13
EP3242557A1 (en) 2017-11-15
WO2016112312A1 (en) 2016-07-14
MX2017009011A (es) 2017-10-02
CO2017007823A2 (es) 2018-01-05
EP3242557A4 (en) 2018-09-05
US20180264061A1 (en) 2018-09-20
JP2018509382A (ja) 2018-04-05
BR112017014750A2 (pt) 2018-06-19
CA2972996A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
EP4025537A4 (en) Low-energy water treatment
BR112017006664A2 (pt) terapias de combinação
CL2017002567A1 (es) Composiciones para modular la expresión de c9orf72
AU362319S (en) Pet treat
CL2017001790A1 (es) Método para tratar diarrea en animales de compañía
TW201614072A (en) CAR-T lymphocytes engineered to home to lymph node B cell zone, skin, or gastrointestinal tract
DK3215611T3 (da) Peptid-medieret indgivelse af rna-guidet endonuklease i celler
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
ZA201601028B (en) Floating lake and methods of treating water within the floating lake
MX383245B (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
MX375838B (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activación de células estrelladas hepáticas.
MX2018005348A (es) Composiciones y metodos para transduccion de tumores.
MX2015015031A (es) Metodos y composiciones de cemento que utilizan fibras de poliolefina tratadas.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
DK3460052T3 (da) Forbedrede allogene dendrittiske celler til anvendelse i behandling af cancer
GB2533024A (en) Device and system for treatment of fish
EP3385231A4 (en) OZONE WATER TREATMENT SYSTEM USING LOW ENERGY
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
DK3419673T3 (da) Genterapi til behandling af sygdom i nethindens tapceller
DK3535530T3 (da) Varmtvands- og energilagring
IL288144A (en) Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
BR112017012134A2 (pt) prevenção e tratamento de condições inflamatórias
IL267231A (en) Methods of treating diseases associated with ilc2 cells
BR112015023260A2 (pt) método de tratamento de grão com ozônio